Lifecore Biomedical Inc. (LFCR) Stock: Analyzing the Market Value

, and the 36-month beta value for LFCR is at 1.03. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”

The average price suggested by analysts for LFCR is $9.50, which is $1.22 above the current market price. The public float for LFCR is 29.04M, and currently, shorts hold a 8.34% of that float. The average trading volume for LFCR on June 19, 2023 was 1.22M shares.

Top 5 AI Stocks to Buy for 2023

The artificial intelligence (AI) revolution is already here. And it’s about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.

Click Here to Download the FREE Report.


LFCR) stock’s latest price update

Lifecore Biomedical Inc. (NASDAQ: LFCR) has experienced a decline in its stock price by -3.16 compared to its previous closing price of 8.55. However, the company has seen a fall of -3.83% in its stock price over the last five trading days.

LFCR’s Market Performance

Lifecore Biomedical Inc. (LFCR) has experienced a -3.83% fall in stock performance for the past week, with a 66.27% rise in the past month, and a 395.81% rise in the past quarter. The volatility ratio for the week is 4.52%, and the volatility levels for the past 30 days are at 10.56% for LFCR. The simple moving average for the past 20 days is 4.62% for LFCR’s stock, with a 20.32% simple moving average for the past 200 days.

Analysts’ Opinion of LFCR

Many brokerage firms have already submitted their reports for LFCR stocks, with Stephens repeating the rating for LFCR by listing it as a “Equal-Weight.” The predicted price for LFCR in the upcoming period, according to Stephens is $2 based on the research report published on March 20th of the current year 2023.

LFCR Trading at 45.76% from the 50-Day Moving Average

After a stumble in the market that brought LFCR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -30.74% of loss for the given period.

Volatility was left at 10.56%, however, over the last 30 days, the volatility rate increased by 4.52%, as shares surge +58.02% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +123.18% upper at present.

During the last 5 trading sessions, LFCR fell by -3.83%, which changed the moving average for the period of 200-days by -18.34% in comparison to the 20-day moving average, which settled at $8.07. In addition, Lifecore Biomedical Inc. saw 27.78% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at LFCR starting from WYNNEFIELD PARTNERS SMALL CAP, who purchase 345,260 shares at the price of $7.97 back on Nov 25. After this action, WYNNEFIELD PARTNERS SMALL CAP now owns 1,972,853 shares of Lifecore Biomedical Inc., valued at $2,751,722 using the latest closing price.

WYNNEFIELD PARTNERS SMALL CAP, the 10% Owner of Lifecore Biomedical Inc., purchase 282,486 shares at $7.97 during a trade that took place back on Nov 25, which means that WYNNEFIELD PARTNERS SMALL CAP is holding 2,438,180 shares at $2,251,413 based on the most recent closing price.

Stock Fundamentals for LFCR

Current profitability levels for the company are sitting at:

  • -1.94 for the present operating margin
  • +27.11 for the gross margin

The net margin for Lifecore Biomedical Inc. stands at -34.19. The total capital return value is set at -1.08, while invested capital returns managed to touch -25.82. Equity return is now at value -107.90, with -28.40 for asset returns.

Based on Lifecore Biomedical Inc. (LFCR), the company’s capital structure generated 168.90 points at debt to equity in total, while total debt to capital is 62.81. Total debt to assets is 53.12, with long-term debt to equity ratio resting at 11.01. Finally, the long-term debt to capital ratio is 4.09.

When we switch over and look at the enterprise to sales, we see a ratio of 2.61, with the company’s debt to enterprise value settled at 0.35. The receivables turnover for the company is 3.14 and the total asset turnover is 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.70.


In conclusion, Lifecore Biomedical Inc. (LFCR) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.